amleto d’agostino, fondazione sdn, 25 ottobre 2013 · amleto d’agostino, fondazione sdn, 25...
TRANSCRIPT
Amleto D’Agostino, Fondazione SDN, 25 Ottobre 2013
High quality offerin terms of
facilities and tools (technology
platforms)
Extraordinary offerin terms of
knowledge and research
capabilities
Feeble bio-industrial
development
Key issues for Campania Bio-community
Strong science base centres with
a high skilledworkforce
CAMPANIA BIOSCIENCE: NETWORK IN PROGRESS
CAMPANIA BIOSCIENCE: NETWORK IN PROGRESS
Scientific Offer
Extraordinary offer in terms of biology sciences-oriented research institutes/centres
4 Universities
5 National Research Council Institutes and “Anton Dohrn” Zoological Institute of
Naples
3 Biotechnology research networks: BioTekNet; DFM; GEAR
3 No profit bio-consortiums for research: CEINGE, TIGEM and BIOGEM
30.000 square meters of laboratories
60 patents
"BIO" AREA - EMPLOYEES IN R&D IN "CONVERGENCE" REGIONS
Source: Cineca data (on February 2011) and National Research Council (CNR)
HEALTH AND BIOTECH - BENCHMARK EMPLOYEES IN R&D
Source: Cineca data (on February 2011) and National Research Council (CNR)
HEALTH AND BIOTECH - SCIENTIFIC PUBLICATIONS
0 10 20 30 40 50 60Numero scienziati presenti nella Top Italian Scientists
Region
i ana
lizzate
Campania
Sicilia
Puglia
Calabria
Source: Cineca data (on February 2011) and National Research Council (CNR)
NUMBER OF BIOTECH COMPANY, TURNOVER, INVESTMENTS IN R&D AND R&D EMPLOYEES
COMPANIES IN CAMPANIA BIO-COMMUNITY
Campania Region currently hosts pretty remarkable bio-companiessuch as HARDIS belonging to KEDRION group; ALTERGONITALIA (linked to the Swiss company IBSA); OKAIROS;NOVARTIS; DSM and the newborn company ARTERRABIOSCIENCE. In spite of its outstanding industrial growth forsouthern Italy, the number of the industrial companies is far behindthe strong presence of high level research centers andcompetences
MAIN COMPETENCES
Gene expression and proteomics
Bioinformatics
Pharmacogenomics
Industrial Biotechnologies
Nutraceuticals, cosmeceuticals and functional foods
Bioremediation and biodegradation
Molecular diagnostics
Gene therapy
MAIN CHALLENGES
To finalize financial efforts by a medium-long-term strategic approach
To improve results and Intellectual Property exploitation
To enhance technology transfer
To support transnational researches and projects
FIRST CLUSTERING STEP: THE IMPLEMENTATION OF REGIONAL NETWORK
Centro Regionale di Competenza
in Biotecnologie Industriali
Beginning 2008
14.12.2007
14.12.2007
SECOND CLUSTERING STEP: THE IMPLEMENTATION OF A CLUSTER
Nutraceutis and Food
Industries
Diagnostic Industries
Pharma Industries
STATE OF THE ART
22/03/2011• Presentazione studio di fattibilità
23/04/2012
• Approvazione dello studio di fattibilitàCampania Bioscience da parte del MIUR
07/08/2012
• Stipula Accordo di Programma QuadroMIUR – Regione Campania
Next step (November 2013): Evaluation of the executive project
Feasibility Study presentation to build theCluster Campania Bioscience
Feasibility Study of Campania Bioscience approval by theItalian Ministry for Universities and Research
Conclusion of Framework Programme Agreement MIUR-Campania Region
14/02/2013• Establishment of Campania Bioscience SCaRL ( Ltd.
Company)
Legal name Campania Bioscience SCaRL
Legal status Società Consortile a Responsabilità Limitata
MembersResearch organizationsCompaniesScientific Parks
Shares44 % Research organizations44 % Companies12 % Scientific Parks
Object No-profit
Capital 1,7 Millions Euros
LEGAL ENTITY OF THE CLUSTER
CAMPANIA BIOSCIENCE’S Shareholders
N. 8 Research organizations
48 companies:13 big enterprises11 medium enterprises24 small enterprises
THE INDUSTRIAL SHAREHOLDERS
THE INDUSTRIAL SHAREHOLDERS
THE INDUSTRIAL SHAREHOLDERS
UNIVERSITIES, RESEARCH ORGANIZATIONS AND SCIENTIFIC PARKS
GOVERNANCE OF CAMPANIA BIOSCIENCE
Researchorganizations
Companies TT Structures
3 3 1
Board od Directors
Shareholders’ Assembly
Chairman
General Manager
Audit Committee
GTT 4
Diagnostic and
Biomedical
GTT 3
Nutraceutical
and
Cosmeceutical
GTT 5
New Therapies
GTT 1Technology transfer,
Networking. Dissemination
GTT 2Training and
development of human
resources
Confindustria
1
Board of management
GTT M Monitoringexecutive projects
GTT MFranco Salvatore (Ceinge)GiovannangeloOriani (Ceinge)Francesco Rossi (SUN)Mario De Rosa (SUN)Chiara Schiraldi(SUN)Paolo Netti (FII)Tommaso Russo (FII)Vincenzo Pavone (FII)Francesco Beguinot (FII)Fabrizio Ferrando (Esaote)
GTT 1 Roberto Vona(FII)Mario Sorrentino (SUN)Alessandro Indiveri(Technapoli)Pino Manco (CNR)Roberto Tagliaferri(Unisa)Alfonsina Migliozzi(Mataluni)Stefania Spinelli (PST SA)Andrea Di Maso (Biogem)Gianluca Di Brina (Engineering) Concetta D’Orio (BioTekNet)
GTT 2 Vincenzo Maggioni (SUN) Roberto Parente (Unisa) Giuseppe Zollo (FII) Giovanni De Simone (FII)Maria Rosaria Napolitano (Unisannio)Gabriella Minchiotti (CNR)Domenico Gambacorta (Biogem)Paola Mazzocca(TechnapolI)Isabella Colamarco (PST SA)Achille Masturzo(BioTekNet)
GTT 3 Gabriele Riccardi (FII)Ettore Novellino (FII)Chiara SchiraldiElena De Marco (Mataluni)Agostino CasapulloBarbara Nicolaus (CNR) Luigi Fontana (UNISA) Pasquale Vito (Unisannio)Salvatore Riccio (UNISA) Andrea Giori(IBSA)
GTT 4Alberto Luini (CNR)Alessandro Nencioni(Esaote)Giuseppe Castaldo (FII)Marco Salvatore (FII)Lucia Altucci (SUN)Vincenzo Nigro(SUN)Raffaele Riccio (UNISA) Francesco Mancini (Unisannio)Mario De Felice (FII) Massimiliano Minale (Damor)
GTT 5Fortunato Ciardiello (SUN)Stefania Amorosi (Altergon)Gianfranco Di Renzo (FII)Lucio Pastore (FII)Liberato Berrino(SUN)Aldo Pinto (UNISA)Vittorio de Franciscis (CNR) Claudio Pisano (Biogem)Francesco Izzo (Pascale) Anna Tortiglione (Damor)
LINE 1 – R&D ACTIVITIES OF THE CLUSTER
Line 1 – Infrastructures and Industrial Research
Enforce and integrate the R&D infrastructures(companies and research organizations) andimplement industrial research activities in thefollowing three thematic areas:
1) Development and Production of nutraceuticals andcosmeceuticals
2) Diagnostics, biosensors and innovativetechnologies for biomedical industry
3) New therapies
CAMPANIA BIOSCIENCE: R&D PROJECTS
1. Strategies for the recovery of bioactive compounds from waste in the foodindustry
2. Design, development and production of functional foods and / or enriched
3. Development and testing of molecules with nutraceutical and cosmeceuticalproperties
4. New strategies for medical and molecular diagnosis and for food traceabilityand monitoring
5. New strategies for medical and molecular diagnosis and for food traceabilityand monitoring
6. Smart materials and new devices for biomedical applications
7. Preclinical development of new therapies and innovative strategies for theproduction of molecules with pharmacological activity
8. Preclinical and phase o and 1 clinical evaluation of molecules withnutraceutical, cosmeceutical and pharmaceutical properties and/or newindications for already approved compounds
ECONOMIC OPPORTUNITIES
HEALTH CAGR 2009-2014
EU market 2008 (billions $)
Nutraceuticals 4,3% 60,33
In vitro diagnosticsand imaging
5,3% 16,10
New therapies 10% 132,48
Total 208,91
2008 European data on Health market (including nutraceuticals, diagnostics in vitroand imaging and new therapies) was US$ 208.91 billions. Growth estimation peryear is more than 6% from 2009 to 2014.
LINE 2 AND 3 – TRAINING AND CLUSTER START-UP
Line 2 – Human Resources ValorisationTraining activities of technical profiles in line with theindustrial research projects of the Cluster and otheractivities to attract young talents
Line 3 – Start-up of the Cluster and activities of marketing,internationalisation and technology transferManagement and technology transfer activities supportingnewcos and start-up
PRIORITIES OF HORIZON 2020 AND CLUSTER VISION
Priorities of Horizon 2020: Demografic change, wellbeing, food security
Technology objectives of Campania Bioscience Cluster:
1) Nutraceutical development2) Growth and children products3) Functional food4) Innovative cosmeceuticals5) Food genetic-molecular tracking
Priorities of Horizon 2020: Health, biotechnologyand advanced manifacturing
Technology objective of Campania Bioscience Cluster:
1) New therapies2) Pharma treatment customization3) Systems for molecular and imaging diagnostics4) Biomedical technologies5) Innovative bioprocesse
PRIORITIES OF HORIZON 2020 AND CLUSTER VISION
…….To Europe
Il Cluster campano Salute, Biotecnologie e Agroalimentare
(Contratto di Rete)
Le Bioregioneuropee
Il Cluster tecnologico nazionale delle
Scienze della Vita
AliseiMarea (APP)
M2Q (APP)
Sorriso (APP)
Ehealthnet (APP)
Biocam (APP)
Dr Amleto D’Agostino, General Manager Campania BioscienceTel +390815667678Mail [email protected]